The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations
Open accessAbstract
Germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 (encoded by TEK) cause a rare, inherited form of venous anomaly known as a mucocutaneous venous malformation (VMCM; refs. 1, 2, 3 and V.W., N.L., M.U., A. Irrthum, L.M.B. et al., unpublished data). We identified a somatic 'second hit' causing loss of function of TIE2 in a resected VMCM and assessed whether such localized, tissue-specific events have a role in the etiology of sporadic venous malformations, which are far more common. We identified eight somatic TEK mutations in lesions from 28 of 57 individuals (49.1%) with sporadic venous malformations; the mutations were absent from the individuals' blood and control tissues. The somatic mutations included one causing a frequent L914F substitution and several double mutations in cis, all of which resulted in ligand-independent TIE2 hyperphosphorylation in vitro. When overexpressed in human umbilical vein endothelial cells, the L914F mutant was abnormally localized and responded to ligand, in contrast to wild-type TIE2 and the common, inherited R849W mutant, suggesting that the mutations have distinct effects. The presence of the same mutations in multifocal sporadic venous malformations in two individuals suggests a common origin for the abnormal endothelial cells at the distant sites. These data show that a sporadic disease may be explained by somatic changes in a gene causing rare, inherited forms and pinpoint TIE2 pathways as potential therapeutic targets for venous malformations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., & Qin, Y. (1995) · Nature · doi:10.1038/376070a0 · Cited by 1,820
Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M., Auerbach, A., & Breitman, M. L. (1994) · Genes & Development · doi:10.1101/gad.8.16.1897 · Cited by 985
Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2
Vikkula, M., Boon, L. M., Iii, K. L. C., Calvert, J. T., Diamonti, A. J., Goumnerov, B., Pasyk, K. A., Marchuk, D. A., Warman, M. L., Cantley, L. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81814-0 · Cited by 802
Self-citationIn and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases
Hebert, D. N., & Molinari, M. (2007) · Physiological Reviews · doi:10.1152/physrev.00050.2006 · Cited by 671
Dumont, D. J., Fong, G., Puri, M. C., Gradwohl, G., Alitalo, K., & Breitman, M. L. (1995) · Developmental Dynamics · doi:10.1002/aja.1002030109 · Cited by 539
Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1715 · Cited by 471
Self-citationSato, T. N., Qin, Y., Kozak, C. A., & Audus, K. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9355 · Cited by 462
Tie receptors: new modulators of angiogenic and lymphangiogenic responses
Jones, N., Iljin, K., Dumont, D. J., & Alitalo, K. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067005 · Cited by 418
Cited by
Dejana, E., Tournier-Lasserve, E., & Weinstein, B. M. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.004 · Cited by 788
Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era
McDonald, J., Wooderchak-Donahue, W., VanSant Webb, C., Whitehead, K., Stevenson, D. A., & Bayrak-Toydemir, P. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00001 · Cited by 726
Vascular heterogeneity and specialization in development and disease
Potente, M., & Mäkinen, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.36 · Cited by 653
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Self-citationSomatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
Nikolaev, S. I., Vetiska, S., Bonilla, X., Boudreau, E., Jauhiainen, S., Rezai Jahromi, B., Khyzha, N., DiStefano, P. V., Suutarinen, S., Kiehl, T.-R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709449 · Cited by 467
Lesca, G., Rudolf, G., Bruneau, N., Lozovaya, N., Labalme, A., Boutry-Kryza, N., Salmi, M., Tsintsadze, T., Addis, L., Motte, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2726 · Cited by 439
GRIN2A mutations cause epilepsy-aphasia spectrum disorders
Carvill, G. L., Regan, B. M., Yendle, S. C., O'Roak, B. J., Lozovaya, N., Bruneau, N., Burnashev, N., Khan, A., Cook, J., Geraghty, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2727 · Cited by 376
Genetics of lymphatic anomalies
Brouillard, P., Boon, L., & Vikkula, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71614 · Cited by 355
Self-citationSomatic Activating PIK3CA Mutations Cause Venous Malformation
Limaye, N., Kangas, J., Mendola, A., Godfraind, C., Schlögel, M. J., Helaers, R., Eklund, L., Boon, L. M., & Vikkula, M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.011 · Cited by 351
Self-citationISSVA Classification of Vascular Anomalies and Molecular Biology
Kunimoto, K., Yamamoto, Y., & Jinnin, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042358 · Cited by 309
Amyere, M., Revencu, N., Helaers, R., Pairet, E., Baselga, E., Cordisco, M., Chung, W., Dubois, J., Lacour, J.-P., Martorell, L., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026886 · Cited by 302
Self-citationRevencu, N., Boon, L. M., Mendola, A., Cordisco, M. R., Dubois, J., Clapuyt, P., Hammer, F., Amor, D. J., Irvine, A. D., Baselga, E., et al. (2013) · Human Mutation · doi:10.1002/humu.22431 · Cited by 294
Self-citationMosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy
Al-Olabi, L., Polubothu, S., Dowsett, K., Andrews, K. A., Stadnik, P., Joseph, A. P., Knox, R., Pittman, A., Clark, G., Baird, W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98589 · Cited by 292
The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway
Thurston, G., & Daly, C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006650 · Cited by 266
Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity
Souma, T., Tompson, S. W., Thomson, B. R., Siggs, O. M., Kizhatil, K., Yamaguchi, S., Feng, L., Limviphuvadh, V., Whisenhunt, K. N., Maurer-Stroh, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85830 · Cited by 259
Characterization of ANGPT2 mutations associated with primary lymphedema
Leppänen, V.-M., Brouillard, P., Korhonen, E. A., Sipilä, T., Jha, S. K., Revencu, N., Labarque, V., Fastré, E., Schlögel, M., Ravoet, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8013 · Cited by 49
Self-citationAngiopoietin–TIE2 feedforward circuit promotes PIK3CA-driven venous malformations
Kraft, M., Schoofs, H., Petkova, M., Andrade, J., Grosso, A. R., Benedito, R., De Roo, A.-K., Boon, L. M., Vikkula, M., Kapp, F. G., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00655-9 · Cited by 28
Self-citationKapp, F. G., Bazgir, F., Mahammadzade, N., Mehrabipour, M., Vassella, E., Bernhard, S. M., Döring, Y., Holm, A., Karow, A., Seebauer, C., et al. (2024) · Angiogenesis · doi:10.1007/s10456-024-09934-8 · Cited by 20
Inactive β1-integrin acts as a junctional scaffold for angiopoietin/TIE2/FOXO1 signaling
Sipilä, T., Ponna, S. K., Venkatesha Murthy, A., Pink, A., Enkavi, G., Bohra, S. K., Lewna, K., Ganesh, K., Liu, Q., Korhonen, M., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci190552
“Inactivating gene variants in the ANGPT receptor TEK (encoding the TIE2 RTK) and in ANGPT1 are linked to defective Schlemm’s canal formation leading to glaucoma (8, 9), whereas activating TEK mutations cause venous malformations (10).”
(2023) · doi:10.1101/2023.11.13.23298448
Metadata
- Authors
- Limaye, N., Wouters, V., Uebelhoer, M., Tuominen, M., Wirkkala, R., Mulliken, J. B., Eklund, L., Boon, L. M., & Vikkula, M.
- Venue
- Nature Genetics
- Published
- 2008-12-14
- Volume
- 41
- Issue
- 1
- Pages
- 118-124
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1990275904
- Cited by
- 492
- References
- 25
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.